Hypothyroid myopathy caused by interferon-α therapy for chronic hepatitis C

Clinical Neurology

Volumn 45, Issue 6, 2005, Pages 441-444

  Nagane, Yuriko ^a   Utsugisawa, Kimiaki ^a   Kizawa, Hideki ^a   Kondoh, Ryushi ^a   Terayama, Yasuo ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Blocking type TSH receptor antibody; Chronic hepatitis C; Hypothyroid myopathy; Interferon

Indexed keywords

ALPHA INTERFERON; CREATINE KINASE; LIOTHYRONINE; MYOGLOBIN; THYROID ANTIBODY; THYROID HORMONE; THYROTROPIN; THYROTROPIN RECEPTOR; ALPHA2B INTERFERON; ANTIVIRUS AGENT; RIBAVIRIN;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ARM MUSCLE; ARTICLE; CASE REPORT; CREATINE KINASE BLOOD LEVEL; HASHIMOTO DISEASE; HEPATITIS C; HUMAN; HUMAN TISSUE; HYPOTHYROID MYOPATHY; HYPOTHYROIDISM; LEG MUSCLE; MALE; MUSCLE BIOPSY; MUSCLE WEAKNESS; MYOPATHY; QUADRICEPS FEMORIS MUSCLE; RARE DISEASE; SYMPTOMATOLOGY; THYROID FUNCTION TEST; TREATMENT OUTCOME; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; MUSCLE DISEASE;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; HYPOTHYROIDISM; INTERFERON ALFA-2B; MALE; MIDDLE AGED; MUSCULAR DISEASES; RIBAVIRIN;

EID: 23444443872     PISSN: 0009918X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Kirchner H: Interferons, a group of multiple lymphokines. Springer Semin Immunopathol 1984; 7: 347-374
2. McMurray RW, Elbourne K: Hepatitis C virus infection and autoimmunity. Semin Arthritis Rheum 1997; 26: 689-701
3. Dusheiko G: Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997; 26 (suppl. 1): 112S-121S
4. Zuckerman E, Kessel A, Slobodin G, et al: Antiviral treatment down-regulates peripheral B-cell CD81 expression and CD5 expansion in chronic hepatitis C virus infection. J Virol 2003; 77: 10432-10436
5. Antonelli A, Ferri C, Pampana A, et al: Thyroid disorders in chronic hepatitis C. Am J Med 2004; 117: 10-13
6. Carella C, Mazziotti G, Morisco F, et al: The addition of ribavirin to interferon-α therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism. Eur J Endocrinol 2002; 146: 743-749
7. Ronnblom LE, Aim GV, Oberg KE: Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991; 115: 178-183
8. Carella C, Amato G, Bondi B, et al: Longitudinal study of antibodies against thyroid in patients undergoing interferon-α therapy for HCV chronic hepatitis. Horm Res 1995; 44: 110-114
9. Watanabe U, Hashimoto E, Hisamitsu T, et al: The risk factor for development of thyroid disease during interferon-α therapy for chronic hepatitis C. Am J Gastroenterol 1994; 89: 399-403
10. Ghilardi G, Gonvers J-J, So A: Hypothyroid myopathy as a complication of interferon alpha therapy for chronic hepatitis C virus infection. Br J Rheumatol 1998; 37: 1349-1351